All In Biotech

Free tool

FAERS Monitor: Vyndaqel

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211996 or its brand name (Vyndaqel, Tafamidis Meglumine). Reports on generic versions are filed under their own applications.

Reports

4,834

Serious

4,224

87% of reports

Hospitalization

1,470

Death reported

1,920

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death1,404
  • cardiac failure537
  • off label use417
  • dyspnoea240
  • cardiac failure chronic194
  • product use in unapproved indication190
  • atrial fibrillation182
  • fatigue174
  • condition aggravated159
  • disease progression146
  • asthenia135
  • fall134
  • dizziness129
  • diarrhoea104
  • weight decreased101

Reports by year received

View as table
YearReports
20125
20134
20142
201522
201610
201710
201830
2019637
2020833
2021583
2022750
2023429
2024478
2025663
2026378

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cardiac failure chronicSignal194207.5180.137,858
cardiac failureSignal53729.327.014,605
atrial fibrillationSignal1828.17.11,137
deathSignal1,4047.16.87,655
disease progressionSignal1465.44.6518
product use in unapproved indicationSignal1903.32.9312
condition aggravatedSignal1592.32.0114
off label useSignal4172.11.9240
dyspnoea2401.81.695
fall1341.81.543
weight decreased1011.61.321
asthenia1351.61.327
dizziness1291.10.92
fatigue1741.00.80
diarrhoea1040.70.613

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.